IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY

• US 20190328869A1
• Filed: 10/10/2017
• Published: 10/31/2019
• Est. Priority Date: 10/10/2016
• Status: Abandoned Application

• Current Assignee: Transgene S.A. (Compagnie Merieux Alliance SAS)
• Original Assignee: Transgene S.A. (Compagnie Merieux Alliance SAS)
• Inventors: Lelu-Santolaria, Karine, Kratzer, Roland, Martin, Perrine
• Application Number:
  US16/339,417
• Publication Number:
  US 20190328869A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/555 characterised by a specific combination antigen/adjuvant
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/235 Adenoviridae
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2710/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2799/023 where the vector is derived from a poxvirus

Abstract

The present invention provides an immunotherapeutic composition for use in combination with one or more MDSC (Myeloid-derived suppressor cells) modulator(s) and a kit of parts comprising such components as well as methods using such components in combination. The invention also provides the use of Phosphodiesterase-5 (PDE5) inhibitors for reversing immunosuppression in chronic infectious diseases. The invention is of very special interest in treating or preventing diseases, especially chronic infectious diseases such as hepatitis B.

Claims

1-25. -25. (canceled)

26. A combination comprising at least (a) a composition comprising a therapeutically effective amount of an immunotherapeutic product and at least (b) one or more MDSC modulator(s).

27. The combination of claim 26, wherein said immunotherapeutic product comprises a plasmid or a viral vector.

28. The combination of claim 26, wherein said viral vector is obtained from a poxvirus or an adenovirus.

29. The combination of claim 28, wherein said immunotherapeutic product comprises a replication-defective adenovirus obtained from a human adenovirus of serotype 5 (Ad5) which is defective for E1 and/or E3 function(s).

30. The combination of claim 26, wherein the immunotherapeutic product includes or encodes one or more antigen(s) selected from the group consisting of cancer antigen(s) and antigen(s) originating from an infectious organism or associated with a disease or condition caused by an infectious organism.

31. The combination of claim 30, wherein said one or more antigens are selected from the group consisting of mucin antigens, human papillomavirus (HPV) antigens, hepatitis C virus (HCV) antigens, hepatitis B virus (HBV) antigens, Mycobacterium tuberculosis (Mtb) antigens;

and any combination thereof.

32. The combination of claim 31, wherein said one or more antigens are HBV antigens selected from the group consisting of HBV polymerase, HBc, and HBs antigens.

33. The combination of claim 32, wherein:

a) said HBc antigen comprises an amino acid sequence that is at least 80% identical to SEQ ID NO;

1 or SEQ ID NO;

2;

b) said polymerase antigen is defective for the polymerase enzymatic activity and/or for the RNaseH activity exhibited by the native counterpart and comprises an amino acid sequence that is at least 80% identical to SEQ ID NO;

3, SEQ ID NO;

4 or SEQ ID NO;

5; and

/or

c) said HBsAg antigen consists of one or more HBs immunogenic domain(s) comprising an amino acid sequence that is at least 80% identical to SEQ ID NO;

6 or SEQ ID NO;

7.

34. The combination of claim 32, wherein said immunotherapeutic product encodes a fusion protein of HBc, pol, and HbsAg.

35. The combination of claim 34, wherein said fusion protein of HBc, pol, and HbsAg comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

8.

36. The combination of claim 35, wherein said immunotherapeutic product is a replication-defective adenovirus comprising inserted in place of the E1 region a nucleic acid molecule placed under the control of a promoter, and encoding a fusion protein comprising an amino acid sequence as shown in SEQ ID NO:

8.

37. The combination of claim 26, wherein said one or more MDSC modulator(s) comprises a PDE-5 inhibitor capable of antagonizing the activity of a phosphodiesterase subtype 5 (PDE-5).

38. The combination of claim 37, wherein said PDE-5 inhibitor is selected from the group consisting of avanafil, lodenafil, mirodenafil, sildenafil, actetildenafil, hydroxyacetildenafil, dimethylsildenafil, thiomethisosildenafil, tadalafil, vardenafil, udenafil, zaprinast, icariin, sulfoaildenafil, and benzamidenafil.

39. The combination of claim 26, comprising:

a) a composition comprising from about 10⁷ vp to about 10¹² vp of a virus-based immunotherapeutic product, and

b) from about 1 mg to about 200 mg of a PDE5 inhibitor.

40. The combination of claim 39, comprising:

a) about 10⁹ vp, about 10¹⁰ vp or about 10¹¹ vp of an adenoviral vector encoding one or more HBV antigen(s), and

b) daily or every 2 days doses from about 1.5 mg to about 100 mg of sildenafil, taken in one or more doses of 2 mg, 5 mg, 10 mg, 20 mg, 25 mg, 50 mg, or 100 mg.

41. A method for treating or preventing a disease or a pathologic condition in a subject in need thereof or for treating a subject having a condition that would benefit from upregulation of the immune response, comprising administering to said subject a therapeutically effective amount of a combination comprising at least (a) a composition comprising a therapeutically effective amount of an immunotherapeutic product and at least (b) one or more MDSC modulator(s).

42. The method of claim 41, wherein said immunotherapeutic product is formulated for intradermal, transcutaneous, intramuscular, subcutaneous, or intratumoral administration and wherein said one or more MDSC modulator(s) is formulated for oral, sublingual, or intravenous administration.

43. The method of claim 41, wherein said disease or pathologic condition is selected from the group consisting of proliferative diseases, infectious diseases, and acute or chronic inflammatory diseases.

44. The method of claim 43, wherein:

a) said proliferative disease is a cancer selected from the group consisting of renal cancer, bladder cancer, prostate cancer, breast cancer, colorectal cancer, lung cancer, liver cancer, gastric cancer, pancreatic cancer, melanoma, ovarian cancer, and glioblastoma;

or

b) said infectious disease is selected from a viral infection with HPV, HCV, or HBV virus or a bacterial infection with Mycobacterium.

45. The method of claim 41, wherein the MDSC modulator(s) is/are given to the subject before initiating administrations of the immunotherapeutic product.

46. The method of claim 45, wherein the MDSC modulator(s) therapy starts prior to immunotherapeutic product therapy, with continuation of MDSC modulator therapy during immunotherapeutic product therapy.

47. The method of claim 45, wherein the one or more MDSC modulator(s) is given to the subject at least one week before initiating administration(s) of the immunotherapeutic product.

48. The method of claim 41, wherein the administration(s) of the immunotherapeutic product composition is initiated before starting the MDSC modulator(s) therapy.

49. The method of claim 48, wherein the administrations of the one or more MDSC modulator(s) are initiated at the very end of the immunotherapeutic product administration(s) or very shortly after.

50. The method of claim 41, wherein said method comprises a) 3 weekly intradermal, subcutaneous or intramuscular administrations of about 10⁹ vp, about 10¹⁰ vp or about 10¹¹ vp of an adenovirus-based immunotherapeutic product and b) oral administrations of 1.5 to 100 mg of said MDSC modulator(s);

wherein said MDSC modulator(s) is sildenafil.

51. The method of claim 41, wherein said combination is administered in association with a conventional therapeutic modality available for treating or preventing the targeted disease or pathological condition.

52. The method of claim 51, wherein the immunotherapeutic product encodes HBV antigens and the combination is administered in association with nucleos(t)ide analogs (NUCs).

53. A method for decreasing the levels of HBsAg and/or HBV viral load in the serum of a subject diagnosed as having an HBV infection, comprising administering to said subject a therapeutically effective amount of a combination comprising at least (a) a composition comprising a therapeutically effective amount of an immunotherapeutic product and at least (b) one or more MDSC modulator(s).

54. The method of claim 53, wherein the immunotherapeutic product is a replication-defective adenovirus comprising inserted in place of the E1 region a nucleic acid molecule placed under the control of a promoter, and encoding a fusion protein of HBc, pol, and HbsAg, and the MDSC modulator(s) comprise(s) a PDE-5 inhibitor.

55. A method for treating or preventing a chronic infectious disease in a subject in need thereof or for reversing immunosuppression in a subject having a chronic infectious disease, comprising administering to said subject a PDE-5 inhibitor.

56. The method of claim 55, wherein said infectious disease is chronic hepatitis B.

57. The method of claim 55, wherein the PDE-5 inhibitor is administered in association with a conventional therapeutic modality available for treating or preventing said chronic infectious disease.